RecruitingPhase 2NCT06559163
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus
Sponsor
Zenas BioPharma (USA), LLC
Enrollment
190 participants
Start Date
Sep 17, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria7
- Males and females, ≥ 18 to ≤ 70 years of age
- Diagnosed with SLE at least 24 weeks prior to screening and meets the 2019 EULAR/ACR classification criteria.
- Patient has all 3 of the following based on features active on the day of the visits:
- hSLEDAI ≥ 6 and clinical hSLEDAI ≥ 4 at screening, and clinical hSLEDAI ≥ 4 at Day 1 Note: Clinical points exclude laboratory tests, except proteinuria.
- BILAG-2004 Grade A or B in ≥ 1 organ system at screening and Day 1.
- In the opinion of the investigator and the central adjudicator, there is sufficient disease activity to warrant enrollment into a clinical study with an investigational agent.
- Patients must be treated with one or more of the following background nonbiologic lupus standard of care therapies: oral corticosteroid, antimalarial, and/or immunosuppressant.
Exclusion Criteria5
- Active lupus nephritis for which, in the opinion of the investigator or the central adjudicator, current medications are insufficient for patient's safety or additional therapy that is not permitted in the protocol is needed.
- A history of thrombosis or embolism in the previous 6 months before the Screening visit, or previous 12 months associated with antiphospholipid syndrome (APS) or another relevant hypercoagulable state.
- Any active skin conditions other than cutaneous lupus erythematosus (CLE) that may interfere with the study assessment of CLE such as, but not limited to, psoriasis, dermatomyositis, and systemic sclerosis.
- Active severe neuropsychiatric or central nervous system SLE.
- Current inflammatory disease other than SLE (including, but not limited to, rheumatoid arthritis, psoriatic arthritis, spondyloarthropathy, reactive arthritis, scleroderma, dermatomyositis) that may interfere with the assessment of lupus signs and symptoms in the opinion of the investigator or central adjudicator.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGObexelimab
Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.
DRUGPlacebo
Placebo
Locations(82)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06559163
Related Trials
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325225 locations
Study of Systemic Lupus Erythematosus
NCT000013721 location
Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus
NCT058591911 location
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181132 locations
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT0751501417 locations